AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1364953
Drug: Trans‐scleral panretinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans‐scleral panretinal cryocoagulation in combination with cyclo‐cryocoagulation
Trial: 3843217
Drug: Clobazam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (15 to 60 mg per day)
Trial: 3843217
Drug: Clobazam (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (dose changes)
Trial: 3492260
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b (Intron A) high dose (50 X 10(6) IU/m2 intravenously)
Trial: 3492260
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b (Intron A) intermediate dose (30 X 10(6) IU/m2 subcutaneously)
Trial: 3492260
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b (Intron A) low dose (1 X 10(6) IU/m2 subcutaneously)
Trial: 3492260
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b (Intron A) high dose
Trial: 23279371
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block with 15 mL of 0.25% bupivacaine (group B)
Trial: 23279371
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block with 0.25% bupivacaine and 1 μg/kg clonidine (group BC)
Trial: 20122367
Drug: Ondansetron 16
RxNorm normalized name: ondansetron 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 16 mg per day for 10 weeks
Trial: 18004687
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (SB: NaHCO3 300 mg . kg (‐1) body mass)
Trial: 18004687
Drug: Placebo (P:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P: CaCO3 200 mg . kg (‐1) body mass)
Trial: 11094666
Drug: ropivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.125% with fentanyl 2 micrograms/ml
Trial: 8883031
Drug: Antacid, ranitidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid, ranitidine, and misoprostol (prostaglandin E1)
Trial: 8883031
Drug: Antacid and
RxNorm normalized name: Antacid And Antigas
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid and ranitidine
Trial: 8883031
Drug: Antacid, ranitidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid, ranitidine, and bismuth (De Nol)
Trial: 1383590
Drug: Mexicord (antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexicord (antiarrhythmic agent)
Trial: 23385630
Drug: Pegaptanib (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegaptanib (0.3 mg)
Trial: 17164742
Drug: ranolazine 1000
RxNorm normalized name: ranolazine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranolazine 1000 mg b.i.d. (n=22)
Trial: 3898298
Drug: Thymopentin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (50 mg, intravenous injections, 3 times a week for 3 consecutive weeks)
Trial: 29077992
Drug: Exendin‐(9‐39) at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exendin‐(9‐39) at a maximum recommended starting dose of 27 mg kg‐1 day‐1 intravenously
Trial: 27003305
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CCK and Metformin
Trial: 22287353
Drug: FOLFOX4 as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 as conventional neoadjuvant chemotherapy (Group A)
Trial: 22287353
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy delivered 5 days after bevacizumab treatment according to NWTV (Group C)
Trial: 18519778
Drug: rhIL-18 administered
RxNorm normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-18 administered as a 2-h i.v. infusion on 5 consecutive days repeated every 28 days (group A)
Trial: 18519778
Drug: rhIL-18 administered
RxNorm normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-18 administered as a 2-h i.v. infusion once a week (group B)
Trial: 1828543
Drug: Subcutaneous rHuEPO
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rHuEPO (84 ± 9 U/kg body weight/week)
Trial: 1828543
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who were hypertensive prior to rHuEPO therapy
Trial: 7317896
Drug: Propranolol (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (360 mg/day)
Trial: 31859096
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily routine care)
Trial: 26189231
Drug: High-dose midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose midazolam (MDZ) alone (G1)
Trial: 26189231
Drug: Low-dose MDZ
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose MDZ and dexmedetomidine (DEX) (G2)
Trial: 26189231
Drug: High-dose MDZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose MDZ and DEX (G3)
Trial: 26189231
Drug: Low-dose MDZ
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose MDZ and high-dose DEX (G4)
Trial: 26189231
Drug: High-dose MDZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose MDZ and low-dose DEX (G5)
Trial: 26189231
Drug: High-dose DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DEX alone (G6)
Trial: 23737255
Drug: Chewing gum
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gum containing Lactobacillus reuteri (2 × 10^8 CFU per dose), twice daily for 12 weeks
Trial: 19225530
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 or 10 mg)
Trial: 17014994
Drug: Saline intraoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline intraoral injection
Trial: 11411890
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (read radiographs twice, received no intervention)
Trial: 25092108
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine (LC) 1000 mg/d
Trial: 21775070
Drug: Capecitabine (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1,200 mg/m(2)/d Mondays through Friday) and Irinotecan (50 mg/m(2) weekly in four doses) with concurrent radiotherapy (50.4 Gy in 1.8‐Gy fractions) (Arm 1)
Trial: 21775070
Drug: Capecitabine (1,650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1,650 mg/m(2)/d Monday through Friday) and Oxaliplatin (50 mg/m(2) weekly in five doses) with concurrent radiotherapy (50.4 Gy in 1.8‐Gy fractions) (Arm 2)
Trial: 19383889
Drug: 12‐week Better
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12‐week Better Exercise Adherence after Treatment for Cancer intervention
Trial: 17616297
Drug: Tirofiban infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban infusion followed by sirolimus-eluting stent (SES)
Trial: 15135267
Drug: 1mg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg of 17 beta‐estradiol orally combined with 100 mg progesterone
Trial: 15135267
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg transdermally combined with 100 mg progesterone
Trial: 9133340
Drug: Sugar-coated tablet
RxNorm normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sugar-coated tablet formulation (Femavit 1.25)
Trial: 9133340
Drug: Oral suspension
RxNorm normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: 8188994
Drug: Gastrolyte (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrolyte (240 mosm/l)
Trial: 8188994
Drug: Glucolyte (340
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucolyte (340 mOsm/l)
Trial: 3532900
Drug: Ketanserine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserine (80 mg/day for 6 months)
Trial: 29609013
Drug: Bimekizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab (all doses)
Trial: 26884472
Drug: Intranasal glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal glucagon (3 mg)
Trial: 17650792
Drug: Biliary drainage
RxNorm normalized name: PLEURX DRAINAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biliary drainage via endoscope (ENBD) combined with Chinese drug medication (CTG)
Trial: 17650792
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment with ENBD alone (RTG)
Trial: 15618250
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg twice daily for 3 months)
Trial: 15618250
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg for 3 months)
Trial: 10465169
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 30 mg once daily for 14 days
Trial: 31083704
Drug: AW group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AW group (18% oral carbohydrate solution)
Trial: 23528626
Drug: mesalamine (Asacol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalamine (Asacol 800‐mg tablet) 4.8 g/day
Trial: 23528626
Drug: mesalamine (Asacol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalamine (Asacol 800‐mg tablet) 4.8 g/day after excluding ineligible patients
Trial: 19344437
Drug: Valganciclovir (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir (900 mg/day)
Trial: 19344437
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (3000 mg/day)
Trial: 9743397
Drug: Antihistamines (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamines (1 mg/kg diphenhydramine and 4 mg/kg cimetidine)
Trial: 2563688
Drug: Benorylate 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benorylate 4 g
Trial: 25733462
Drug: High-protein preload
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein preload (PRO; 29 g)
Trial: 25733462
Drug: High-calcium preload
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calcium preload (CAL; 1170 mg)
Trial: 11025704
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy for benign prostatic hyperplasia
Trial: 1457115
Drug: ORG 9426
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG 9426 (all doses)
Trial: 6233348
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (n = 24)
Trial: 6233348
Drug: Pharmacotherapy (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (n = 24)
Trial: 6233348
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus pharmacotherapy (n = 22)
Trial: 6233348
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus active placebo (n = 17)
Trial: 6233348
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment modalities
Trial: 26825365
Drug: Clopacin(®) 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopacin(®) 75 mg
Trial: 26825365
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (originator)
Trial: 23054063
Drug: Paracetamol 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1,000 mg + Caffeine 130 mg (PCF)
Trial: 23054063
Drug: Sumatriptan 50
RxNorm normalized name: sumatriptan 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 50 mg (SUM)
Trial: 18370567
Drug: No HMG-CoA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No HMG-CoA reductase inhibitor (statin) therapy
Trial: 16319510
Drug: Gemcitabine (GMC)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GMC) 1,200 mg/m² on days 1 and 8, Cisplatin (CDDP) 75 mg/m² on day 2, repeated every 21 days
Trial: 11752998
Drug: Intrathecal adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal adenosine (2 mg)
Trial: 7484027
Drug: Edrophonium 1
RxNorm normalized name: edrophonium 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1 mg kg‐1
Trial: 7484027
Drug: Suxamethonium 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 1 mg kg‐1 without prior atracurium or anticholinesterase administration
Trial: 2387660
Drug: acetyl-L-carnitine
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetyl-L-carnitine
Trial: 6113021
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g sulphasalazine retention enemas
Trial: 31936621
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BJ) 140 mL
Trial: 27942868
Drug: Experimental Music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Music Therapy Group (EMG)
Trial: 23274144
Drug: FDC capsule
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC capsule containing lamivudine/adefovir dipivoxil 100/10 mg
Trial: 23274144
Drug: Conventional lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional lamivudine 100 mg + adefovir dipivoxil 10 mg tablets
Trial: 23274144
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (FDC and conventional tablets)
Trial: 2005294
Drug: Home-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based treatment
Trial: 26287652
Drug: Hospital-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-based treatment
Trial: 29631747
Drug: Otic drops
RxNorm normalized name: Otic Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otic drops
Trial: 9058223
Drug: Mivacurium chloride
RxNorm normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mivacurium chloride 0.2 mg/kg
Trial: 9058223
Drug: Mivacurium chloride
RxNorm normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mivacurium chloride (both doses)
Trial: 8342319
Drug: Bivalent cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent cold recombinant type A (CRA) vaccines
Trial: 8342319
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza (TI) vaccines
Trial: 29661635
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group receiving intermittent preventive treatment (IPT) with dihydroartemisinin-piperaquine (DP)
Trial: 24702445
Drug: o/w formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: o/w formulation containing licochalcone A, decanediol, menthoxypropanediol and ω‐6‐fatty acids (emollient arm)
Trial: 23984793
Drug: Exenatide +
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide + Metformin
Trial: 22512264
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Metformin
Trial: 20530557
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and home exercise programme
Trial: 20530557
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (inactive ultrasound therapy and inert gel)
Trial: 18206891
Drug: Hcy-lowering agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hcy-lowering agents (folate 1000 mcg, vitamin B12 400 mcg, vitamin B6 10 mg)
Trial: 15531493
Drug: 10 x
RxNorm normalized name: PAD,ABDOMINAL 10 X 12 NONSTERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 x 250 mg T enanthate (TE) im every 3 wk (n = 20)
Trial: 15531493
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 1000 mg TU im every 6 wk (loading dose) followed by 1 x 1000 mg after an additional 9 wk (n = 20)
Trial: 15531493
Drug: 8 x
RxNorm normalized name: Mepilex AG 8 x 8"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 x 1000 mg TU every 12 wk in former TU patients (n = 20)
Trial: 15531493
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 1000 mg TU every 8 wk plus 6 x 1000 mg every 12 wk in former TE patients (n = 16)
Trial: 11570643
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no DEX treatment)
Trial: 18815989
Drug: Group-administered interventions
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-administered interventions
Trial: 16946607
Drug: Chewing gums
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gums (1.3 g xylitol)
Trial: 16946607
Drug: Sucking tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucking tablets (0.8 g xylitol)
Trial: 16946607
Drug: Candy tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candy tablets (1.1 g xylitol)
Trial: 16946607
Drug: Toothpaste (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste (0.1 g xylitol)
Trial: 16946607
Drug: Rinse (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinse (1.0 g xylitol)
Trial: 16946607
Drug: LX rinse
RxNorm normalized name: LX-7101
DrugBank: LX-7101 (DB16009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LX rinse (2.0 g xylitol)
Trial: 16946607
Drug: HX rinse
RxNorm normalized name: Penicillin HX
DrugBank: Amdinocillin (DB01163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HX rinse (6.0 g xylitol)
Trial: 8416021
Drug: Intranasal arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal arginine vasopressin (20 IU)
Trial: 22933207
Drug: Trial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial treatment (TT)
Trial: 22933207
Drug: Routine thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine thrombolytic treatment (Thrx)
Trial: 22933207
Drug: Trial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial treatment (TT) subgroup (refused participation)
Trial: 20424804
Drug: Supplement intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplement intervention (oral liquid nutrition supplementation)
Trial: 18519918
Drug: efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz 600 mg qd for 14 days
Trial: 18519918
Drug: carbamazepine titrated
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: carbamazepine titrated to 400 mg qd for 21 days
Trial: 1660530
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran (28 g [1 oz] twice daily)
Trial: 10328017
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ; 80 mg of TMP and 400 mg of SMZ per tablet; nine tablets taken once daily for three days; total, 27 tablets)
Trial: 10328017
Drug: Tetracycline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (2 g daily for five days)
Trial: 26456162
Drug: Captopril (0.5%)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (0.5%) cream
Trial: 26456162
Drug: Diltiazem (2%)
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem (2%) cream
Trial: 15896919
Drug: Clonidine challenge
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine challenge study for assessment of growth hormone release as a marker of tonic noradrenergic activation.